erlotinib hydrochloride has been researched along with Neoplasms, Skull Base in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Bonneville-Levard, A; Chauffert, B; Chevreau, C; Cupissol, D; Duffaud, F; Fabbro, M; Feuvret, L; Le Cesne, A; Lebellec, L; Mir, O; Noel, G; Penel, N; Saada-Bouzid, E; Vauleon, E; Vinceneux, A | 1 |
| Beer-Furlan, A; Hardesty, DA; Otto, B; Prevedello, DM; Priddy, B | 1 |
2 other study(ies) available for erlotinib hydrochloride and Neoplasms, Skull Base
| Article | Year |
|---|---|
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chordoma; Erlotinib Hydrochloride; Female; France; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Skull Base Neoplasms; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Cerebrospinal Fluid Leak Rhinorrhea after Systemic Erlotinib Chemotherapy for Metastatic Lung Cancer: A Familiar Problem from an Unfamiliar Culprit.
Topics: Adenocarcinoma; Aged; Anti-Bacterial Agents; Antineoplastic Agents; Cerebrospinal Fluid Rhinorrhea; Cranial Fossa, Posterior; Endoscopy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningitis; Nasal Cavity; Natural Orifice Endoscopic Surgery; Sella Turcica; Skull Base; Skull Base Neoplasms | 2017 |